On December 11, 2024 Beroni group reported that immune evasion has become one of the main obstacles in the development of tumor immunotherapy (Press release, Beroni Group, DEC 11, 2024, View Source [SID1234648997]). In the field of invariant natural killer T（iNKT） cell therapy, CD1d in cancer cells is the main tumor antigen presenting molecule that iNKT cells can recognize through its T cell receptor. The genetic and functional variability of CD1d in cancer cells has been considered an important factor in cancer immune evasion. In addition, the tumor specific proteins MUC4 and ITPRIPL1 expressed by refractory pancreatic cancer cells will also pose challenges such as protective immunity to iNKT cell therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In order to unravel the problem of the molecular mechanism of immune evasion of cancer cells during the treatment using iNKT cells and improve the therapeutic effect of iNKT cells, the research team of Beroni Pharmaceutical (Guangdong) Co., Ltd. adopted an adeno-associated virus (AAV) adjuvant strategy to continuously target, identify and label pancreatic cancer cells to express exogenous CD1D-like molecules using our unique pancreatic cancer tropism AAV variant capsid and pancreatic cancer specific gene regulatory elements. By overcoming the challenge of immune evasion mechanism, this innovative AAV adjuvant strategy may significantly improve the effect of iNKT cell therapy and improve the prognosis of pancreatic cancer patients.
In addition, the research team also found that the persistence and recognition killing efficacy of iNKT cells in solid tumors are often constrained by weakened immune suppression mechanisms and unfavorable metabolic environments in the tumor microenvironment. To address this challenge, the research team has developed a metabolic reprogramming strategy for iNKT cells, which optimizes the metabolic health of iNKT cells to better alleviate the immunosuppressive effects of solid tumors caused by the tumor microenvironment. This groundbreaking approach is expected to revolutionize traditional solid tumor immune adoptive therapy by significantly enhancing the metabolic health and tumor killing persistence of iNKT cells.
The research team of Beroni Pharmaceutical (Guangdong) Co., Ltd. is seeking patents for both technologies mentioned above, which marks an important step forward for Beroni Group in developing and improving effective iNKT cell therapy. This marks an important milestone for Beroni Group to continuously expand upon our existing anti-cancer product line. The combination of these two cutting-edge technology is expected to create a new treatment option for advanced solid tumor patients.
Beroni Group will strive to promote clinical application of iNKT cell therapy through unremitting research and clinical development, ultimately to improve prognosis and quality of life bring in cancer patients.